Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11553778 | 0.94 | MAPK14 (0.47) | MAPK14HRH3GABRPGABRDGABRA1 | |
| SCHEMBL11551462 | 0.89 | MAPK14 (0.44) | MAPK14HRH3GABRPGABRDGABRA1 | |
| SCHEMBL11555048 | 0.89 | HRH3 (0.47) | MAPK14HRH3GABRPGABRDGABRA1 | |
| SCHEMBL9672085 | 0.89 | HRH3 (0.49) | HRH3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL2955493 | 0.88 | GABRP (0.47) | MAPK14HRH3GABRPGABRDGABRA1 | |
| SCHEMBL2955972 | 0.86 | KDM4E (0.46) | MAPK14HRH3GABRPGABRDGABRA1 | |
| SCHEMBL10454979 | 0.82 | GABRP (0.45) | MAPK14HRH3GABRPGABRDGABRA1 | |
| SCHEMBL103643 | 0.82 | MMP2 (0.47) | MAPK14HRH3GABRPGABRDGABRA1 | |
| SCHEMBL13985946 | 0.81 | DRD2 (0.36) | MAPK14HRH3GABRPGABRDGABRA1 | |
| SCHEMBL4951636 | 0.80 | MELK (0.43) | MAPK14HRH3GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2807153-B1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-9708275-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2017-07-18 | — | — | US | disclosed |
| US-9708275-B2 | Heterocyclic compounds and methods for their use | NOVARTIS AG (CH) | 2017-07-18 | — | — | US | disclosed |
| US-20160257656-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2016-09-08 | — | — | US | disclosed |
| US-20160257656-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2016-09-08 | — | — | US | disclosed |
| US-20150011565-A1 | Heterocyclic Compounds and Methods For Their Use | NOVARTIS AG (CH) | 2015-01-08 | — | — | US | disclosed |
| US-20150011565-A1 | Heterocyclic Compounds and Methods For Their Use | NOVARTIS AG (CH) | 2015-01-08 | — | — | US | disclosed |
| WO-2013110134-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-08-01 | — | — | WO | disclosed |
| US-7759370-B2 | Sphingosine-1-phosphate (SIP) receptor agonists | Praecis Pharmaceuticals (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| US-5597776-A | ANTAGONIST FOR HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-28 | — | — | US | disclosed |
| US-5491123-A | Herbicides containing 3-aminobenzo(B)thiophenes as antidotes | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-13 | — | — | US | disclosed |
| US-5378677-A | Applying with cyclohexenone derivative | BASF AKTIENGESELLSCHAFT (DE) | 1995-01-03 | — | — | US | disclosed |
| US-5374609-A | Cyclohexenone oxime ethers and their use as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 1994-12-20 | — | — | US | disclosed |
| US-5250505-A | Particularly effective against grasses; low application rate; high selectivity; nonphytotoxic when used for broad-leaf crops and rice | BASF AKTIENGESELLSCHAFT (DE) | 1993-10-05 | — | — | US | disclosed |
| US-4908386-A | Pharmaceuticals | GLAXO GROUP LIMITED (GB) | 1990-03-13 | — | — | US | disclosed |
| EP-0220054-A2 | Ethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 1987-04-29 | — | — | EP | disclosed |
| US-4211783-A | Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257656-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | AGTR2, AGTR1, BDKRB2 | MAPK14 861/4885HRH3 63/4885GABRP 362/4885 |
| US-20150011565-A1 | Heterocyclic Compounds and Methods For Their Use | AGTR2, AGTR1, BDKRB2 | MAPK14 833/4885HRH3 66/4885GABRP 360/4885 |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | CD4, ICOS, NFATC1 | MAPK14 2273/4885HRH3 443/4885GABRP 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.